LFSCvsXBIETF Comparison
VS
F/m Emerald Life Sciences Innovation ETF (LFSC) belongs to the Life Sciences segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. LFSC's top 3 sector exposures are Health Care and Sovereign. In contrast, XBI's top sector exposures are Health Care LFSC is more expensive with a Total Expense Ratio (TER) of 0.79%, versus 0.35% for XBI. LFSC is up 2.35% year-to-date (YTD) with +$5M in YTD flows. XBI performs better with 9.28% YTD performance, and -$19M in YTD flows. Run a side-by-side ETF comparison of LFSC and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
LFSC vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 04/24/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | LFSC XBI | +12.76%+11.52% | +3.57%+4.22% | +2.35%+9.28% | +67.06%+65.29% | n/a+64.93% | n/a-3.74% |
| Flows | LFSC XBI | -$211K+$314M | +$6M-$560M | +$5M-$19M | +$15M+$404M | --$1.15B | -+$839M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | LFSC XBI | +28.73%+30.22% | +26.18%+25.87% | n/a+27.40% | n/a+32.69% |
| Max drawdown | LFSC XBI | -10.65%-7.98% | -16.25%-9.66% | n/a-32.94% | n/a-55.10% |
| Max drawdown duration | LFSC XBI | 47d42d | 135d76d | n/a331d | n/a1822d |
Trading data
LFSC | XBI | |
Last sale 4/27/2026 at 1:30 PM | $37.64 | $133.04 |
| Previous close 04/24/2026 | $37.49 | $133.28 |
| Consolidated volume 04/24/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of March 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
LFSC
is actively managed and doesn’t replicate an indexLFSC | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 4/27/2026 at 1:30 PM
Live
Closed
LFSC | XBI | |
|---|---|---|
| Last price | $37.64 | $133.04 |
| 1D performance | +0.40% | -0.18% |
| AuM | $99.94 M | $8.52 B |
| E/R | 0.79% | 0.35% |
Characteristics
LFSC | XBI | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Emerald Group | State Street Investment Management |
| Benchmark | - | S&P Biotechnology Select Industry Index |
| N° of holdings | 33 | 122 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | October 31, 2024 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
LFSC
USA
90.82%
United Kingdom
7.06%
Other
2.12%
XBI
USA
95.16%
Other
4.84%
Sectors
LFSC
Health Care
78.16%
Other
21.84%
XBI
Health Care
86.79%
Other
13.21%
Diversification
LFSC
Total weight of top 15 holdings out of 15
69.28%
XBI
Total weight of top 15 holdings out of 15
19.71%
Top 15 holdings
Data as of March 31, 2026
LFSC
COGENT BIOSCIENCES
9.11%
LIVANOVA
7.06%
UTD THERAPEUT
5.61%
US00773J2024
5.14%
MIRUM PHARMACEUTICALS INC
5.09%
TRAVERE THERAPEUTICS INC
4.75%
KALVISTA PHARMACEUTICALS INC
4.74%
GUARDANT HEALTH INC
4.38%
BRIDGEBIO PHARMA
4.05%
US6402683063
3.78%
TRANSMEDICS GROUP
3.77%
SAVARA INC
3.74%
TREVI THERAPEUTICS
2.95%
ICU MEDICAL
2.79%
AXSOME THERA CMN STK
2.32%
XBI
APELLIS PHARMACEUTICALS
1.83%
ALKERMES
1.45%
MADRIGAL PHARMACEUTICALS INC
1.38%
TG THERAPEUTICS
1.35%
INSMED
1.34%
SCHOLAR ROCK HOLDING CORP
1.30%
US03770N1019
1.28%
PROTAGONIST THERAPEUTICS INC
1.25%
US86627T1088
1.24%
UTD THERAPEUT
1.24%
US74006W2070
1.24%
ARROWHEAD PHARMACEUTICALS INC
1.23%
COGENT BIOSCIENCES
1.22%
BRIDGEBIO PHARMA
1.19%
PTC THERAPEUTI/D
1.18%
Frequently asked questions about LFSC and XBI
How have the LFSC and XBI ETFs performed in 2026?
As of April 24, 2026, LFSC is up 2.35% year-to-date (YTD), while XBI has returned 9.28%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: LFSC or XBI?
Year-to-date, the LFSC ETF saw +$5M in flows, compared to -$19M for XBI.
Which ETF is more volatile: LFSC or XBI?
Over the past year, LFSC had a volatility of 26.18%, while XBI experienced 25.87%.
Which ETF is bigger: LFSC or XBI?
As of April 24, 2026, LFSC holds $99.94 M in assets under management (AUM), while XBI manages $8.52 B.
What sectors do the LFSC and XBI ETFs invest in?
LFSC leans toward sectors like Health Care. Meanwhile, XBI focuses on Health Care.
What are the top holdings of the LFSC ETF and XBI ETF?
LFSC top holdings include COGENT BIOSCIENCES, LIVANOVA and UTD THERAPEUT. XBI holds in its top three: APELLIS PHARMACEUTICALS, ALKERMES and MADRIGAL PHARMACEUTICALS INC.
Which ETF is more diversified: LFSC or XBI?
LFSC holds 44 securities with 69.28% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 19.71%.
Advertisement
Latest news about LFSC & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
